Selected research
Industry Research
Liposomal and Lipid-based Nanoparticle Drug Industry Research Report 2026
Market perspective
The global Liposomal and Lipid-based Nanoparticle Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Liposomal and Lipid-based Nanoparticle Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Liposomal and Lipid-based Nanoparticle Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Liposomal and Lipid-based Nanoparticle Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Liposomal and Lipid-based Nanoparticle Drug include Acrotech Biopharma, Alnylam, Bausch Health, Chiesi Farmaceutici, CSPC, Fudan-Zhangjiang, Gilead Sciences, Ipsen and Jazz, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Liposomal and Lipid-based Nanoparticle Drug market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Liposomal and Lipid-based Nanoparticle Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Liposomal and Lipid-based Nanoparticle Drug Market by Company
Acrotech Biopharma
Alnylam
Bausch Health
Chiesi Farmaceutici
CSPC
Fudan-Zhangjiang
Gilead Sciences
Ipsen
Jazz
Kinyond
Leadiant Biosciences
Luye Pharma
Pacira
Sayre Therapeutics
TTY Biopharma
Zydus Cadila
Johnson & Johnson
Sun Pharmaceutical
Teva
Takeda
Liposomal and Lipid-based Nanoparticle Drug Segment by Type
Liposomes Drugs
Lipid Nanoparticle Drugs
Liposomal and Lipid-based Nanoparticle Drug Segment by Application
Hospital
Retail Pharmacy
Other
Liposomal and Lipid-based Nanoparticle Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liposomal and Lipid-based Nanoparticle Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Liposomal and Lipid-based Nanoparticle Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liposomal and Lipid-based Nanoparticle Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Liposomal and Lipid-based Nanoparticle Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
Table 5. Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2021-2026) & (US$ Million)
Table 6. Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share by Type (2021-2026)
Table 7. Global Liposomal and Lipid-based Nanoparticle Drug Forecasted Market Size by Type (2027-2032) & (US$ Million)
Table 8. Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share by Type (2027-2032)
Table 9. Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2021-2026) & (US$ Million)
Table 10. Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share by Application (2021-2026)
Table 11. Global Liposomal and Lipid-based Nanoparticle Drug Forecasted Market Size by Application (2027-2032) & (US$ Million)
Table 12. Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share by Application (2027-2032)
Table 13. Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Table 14. Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Region (2021-2026) & (US$ Million)
Table 15. Global Liposomal and Lipid-based Nanoparticle Drug Market Share by Region (2021-2026)
Table 16. Global Liposomal and Lipid-based Nanoparticle Drug Forecasted Market Size by Region (2027-2032) & (US$ Million)
Table 17. Global Liposomal and Lipid-based Nanoparticle Drug Market Share by Region (2027-2032)
Table 18. Liposomal and Lipid-based Nanoparticle Drug Industry Trends
Table 19. Liposomal and Lipid-based Nanoparticle Drug Industry Drivers
Table 20. Liposomal and Lipid-based Nanoparticle Drug Industry Opportunities and Challenges
Table 21. Liposomal and Lipid-based Nanoparticle Drug Market Restraints
Table 22. Global Top Liposomal and Lipid-based Nanoparticle Drug Players by Revenue (US$ Million) & (2021-2026)
Table 23. Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share by Players (2021-2026)
Table 24. Global Liposomal and Lipid-based Nanoparticle Drug Industry Players Ranking, 2024 VS 2025 VS 2026
Table 25. Global Key Players of Liposomal and Lipid-based Nanoparticle Drug, Headquarters and Area Served
Table 26. Global Liposomal and Lipid-based Nanoparticle Drug Players, Product Type & Application
Table 27. Global Players Market Concentration Ratio (CR5 and HHI)
Table 28. Global Liposomal and Lipid-based Nanoparticle Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
Table 29. Players Mergers & Acquisitions, Expansion Plans
Table 30. North America Liposomal and Lipid-based Nanoparticle Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 31. North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2021-2026) & (US$ Million)
Table 32. North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2027-2032) & (US$ Million)
Table 33. Europe Liposomal and Lipid-based Nanoparticle Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 34. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2021-2026) & (US$ Million)
Table 35. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2027-2032) & (US$ Million)
Table 36. Asia Pacific Liposomal and Lipid-based Nanoparticle Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 37. Asia Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Region (2021-2026) & (US$ Million)
Table 38. Asia Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2027-2032) & (US$ Million)
Table 39. South America Liposomal and Lipid-based Nanoparticle Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 40. South America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2021-2026) & (US$ Million)
Table 41. South America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2027-2032) & (US$ Million)
Table 42. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 43. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2021-2026) & (US$ Million)
Table 44. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2027-2032) & (US$ Million)
Table 45. Acrotech Biopharma Company Information
Table 46. Acrotech Biopharma Business Overview
Table 47. Acrotech Biopharma Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026) & (US$ Million)
Table 48. Acrotech Biopharma Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
Table 49. Acrotech Biopharma Recent Developments
Table 50. Alnylam Company Information
Table 51. Alnylam Business Overview
Table 52. Alnylam Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026) & (US$ Million)
Table 53. Alnylam Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
Table 54. Alnylam Recent Developments
Table 55. Bausch Health Company Information
Table 56. Bausch Health Business Overview
Table 57. Bausch Health Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026) & (US$ Million)
Table 58. Bausch Health Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
Table 59. Bausch Health Recent Developments
Table 60. Chiesi Farmaceutici Company Information
Table 61. Chiesi Farmaceutici Business Overview
Table 62. Chiesi Farmaceutici Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026) & (US$ Million)
Table 63. Chiesi Farmaceutici Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
Table 64. Chiesi Farmaceutici Recent Developments
Table 65. CSPC Company Information
Table 66. CSPC Business Overview
Table 67. CSPC Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026) & (US$ Million)
Table 68. CSPC Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
Table 69. CSPC Recent Developments
Table 70. Fudan-Zhangjiang Company Information
Table 71. Fudan-Zhangjiang Business Overview
Table 72. Fudan-Zhangjiang Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026) & (US$ Million)
Table 73. Fudan-Zhangjiang Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
Table 74. Fudan-Zhangjiang Recent Developments
Table 75. Gilead Sciences Company Information
Table 76. Gilead Sciences Business Overview
Table 77. Gilead Sciences Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026) & (US$ Million)
Table 78. Gilead Sciences Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
Table 79. Gilead Sciences Recent Developments
Table 80. Ipsen Company Information
Table 81. Ipsen Business Overview
Table 82. Ipsen Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026) & (US$ Million)
Table 83. Ipsen Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
Table 84. Ipsen Recent Developments
Table 85. Jazz Company Information
Table 86. Jazz Business Overview
Table 87. Jazz Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026) & (US$ Million)
Table 88. Jazz Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
Table 89. Jazz Recent Developments
Table 90. Kinyond Company Information
Table 91. Kinyond Business Overview
Table 92. Kinyond Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026) & (US$ Million)
Table 93. Kinyond Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
Table 94. Kinyond Recent Developments
Table 95. Leadiant Biosciences Company Information
Table 96. Leadiant Biosciences Business Overview
Table 97. Leadiant Biosciences Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026) & (US$ Million)
Table 98. Leadiant Biosciences Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
Table 99. Leadiant Biosciences Recent Developments
Table 100. Luye Pharma Company Information
Table 101. Luye Pharma Business Overview
Table 102. Luye Pharma Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026) & (US$ Million)
Table 103. Luye Pharma Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
Table 104. Luye Pharma Recent Developments
Table 105. Pacira Company Information
Table 106. Pacira Business Overview
Table 107. Pacira Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026) & (US$ Million)
Table 108. Pacira Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
Table 109. Pacira Recent Developments
Table 110. Sayre Therapeutics Company Information
Table 111. Sayre Therapeutics Business Overview
Table 112. Sayre Therapeutics Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026) & (US$ Million)
Table 113. Sayre Therapeutics Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
Table 114. Sayre Therapeutics Recent Developments
Table 115. TTY Biopharma Company Information
Table 116. TTY Biopharma Business Overview
Table 117. TTY Biopharma Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026) & (US$ Million)
Table 118. TTY Biopharma Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
Table 119. TTY Biopharma Recent Developments
Table 120. Zydus Cadila Company Information
Table 121. Zydus Cadila Business Overview
Table 122. Zydus Cadila Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026) & (US$ Million)
Table 123. Zydus Cadila Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
Table 124. Zydus Cadila Recent Developments
Table 125. Johnson & Johnson Company Information
Table 126. Johnson & Johnson Business Overview
Table 127. Johnson & Johnson Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026) & (US$ Million)
Table 128. Johnson & Johnson Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
Table 129. Johnson & Johnson Recent Developments
Table 130. Sun Pharmaceutical Company Information
Table 131. Sun Pharmaceutical Business Overview
Table 132. Sun Pharmaceutical Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026) & (US$ Million)
Table 133. Sun Pharmaceutical Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
Table 134. Sun Pharmaceutical Recent Developments
Table 135. Teva Company Information
Table 136. Teva Business Overview
Table 137. Teva Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026) & (US$ Million)
Table 138. Teva Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
Table 139. Teva Recent Developments
Table 140. Takeda Company Information
Table 141. Takeda Business Overview
Table 142. Takeda Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026) & (US$ Million)
Table 143. Takeda Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
Table 144. Takeda Recent Developments
Table 145. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Liposomal and Lipid-based Nanoparticle Drug Product Image
Figure 5. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 6. Global Liposomal and Lipid-based Nanoparticle Drug Market Share by Type: 2025 VS 2032
Figure 7. Liposomes Drugs Product
Figure 8. Lipid Nanoparticle Drugs Product
Figure 9. Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 10. Global Liposomal and Lipid-based Nanoparticle Drug Market Share by Application: 2025 VS 2032
Figure 11. Hospital Product
Figure 12. Retail Pharmacy Product
Figure 13. Other Product
Figure 14. Global Liposomal and Lipid-based Nanoparticle Drug Market Size (US$ Million), Year-over-Year: 2021-2032
Figure 15. Global Liposomal and Lipid-based Nanoparticle Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032
Figure 16. Global Liposomal and Lipid-based Nanoparticle Drug Market Share by Region: 2025 VS 2032
Figure 17. Global Liposomal and Lipid-based Nanoparticle Drug Market Share by Players in 2025
Figure 18. Global Liposomal and Lipid-based Nanoparticle Drug Manufacturers Established Date
Figure 19. Global Top 5 and 10 Liposomal and Lipid-based Nanoparticle Drug Players Market Share by Revenue in 2025
Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 21. North America Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 22. North America Liposomal and Lipid-based Nanoparticle Drug Market Share by Country (2021-2032)
Figure 23. United States Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 24. Canada Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 25. Mexico Liposomal and Lipid-based Nanoparticle Drug Market Share by Country (2021-2032)
Figure 26. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 27. Europe Liposomal and Lipid-based Nanoparticle Drug Market Share by Country (2021-2032)
Figure 28. Germany Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 29. France Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 30. U.K. Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 31. Italy Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 32. Spain Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 33. Russia Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 34. Netherlands Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 35. Nordic Countries Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 36. Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 37. Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Share by Country (2021-2032)
Figure 38. China Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 39. Japan Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 40. South Korea Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 41. India Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 42. India Liposomal and Lipid-based Nanoparticle Drug Market Share by Country (2021-2032)
Figure 43. Australia Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 44. China Taiwan Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 45. Southeast Asia Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 46. South America Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 47. South America Liposomal and Lipid-based Nanoparticle Drug Market Share by Country (2021-2032)
Figure 48. Brazil Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 49. Argentina Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 50. Chile Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 51. Colombia Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 52. Peru Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 53. Acrotech Biopharma Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
Figure 54. Alnylam Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
Figure 55. Bausch Health Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
Figure 56. Chiesi Farmaceutici Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
Figure 57. CSPC Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
Figure 58. Fudan-Zhangjiang Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
Figure 59. Gilead Sciences Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
Figure 60. Ipsen Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
Figure 61. Jazz Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
Figure 62. Kinyond Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
Figure 63. Leadiant Biosciences Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
Figure 64. Luye Pharma Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
Figure 65. Pacira Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
Figure 66. Sayre Therapeutics Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
Figure 67. TTY Biopharma Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
Figure 68. Zydus Cadila Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
Figure 69. Johnson & Johnson Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
Figure 70. Sun Pharmaceutical Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
Figure 71. Teva Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
Figure 72. Takeda Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
Scope & coverage.
Types
- Liposomes Drugs
- Lipid Nanoparticle Drugs
Applications
- Hospital
- Retail Pharmacy
- Other
Companies covered
- Acrotech Biopharma
- Alnylam
- Bausch Health
- Chiesi Farmaceutici
- CSPC
- Fudan-Zhangjiang
- Gilead Sciences
- Ipsen
- Jazz
- Kinyond
- Leadiant Biosciences
- Luye Pharma
- Pacira
- Sayre Therapeutics
- TTY Biopharma
- Zydus Cadila
- Johnson & Johnson
- Sun Pharmaceutical
- Teva
- Takeda
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Liposomal and Lipid-based Nanoparticle Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Liposomes Drugs
- 2.2.3 Lipid Nanoparticle Drugs
- 2.3 Liposomal and Lipid-based Nanoparticle Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Retail Pharmacy
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Liposomal and Lipid-based Nanoparticle Drug Breakdown Data by Type
- 3.1 Global Liposomal and Lipid-based Nanoparticle Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Liposomal and Lipid-based Nanoparticle Drug Forecasted Market Size by Type (2027-2032)
4 Liposomal and Lipid-based Nanoparticle Drug Breakdown Data by Application
- 4.1 Global Liposomal and Lipid-based Nanoparticle Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Liposomal and Lipid-based Nanoparticle Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Liposomal and Lipid-based Nanoparticle Drug Market Perspective (2021-2032)
- 5.2 Global Liposomal and Lipid-based Nanoparticle Drug Growth Trends by Region
- 5.2.1 Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Liposomal and Lipid-based Nanoparticle Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Liposomal and Lipid-based Nanoparticle Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Liposomal and Lipid-based Nanoparticle Drug Market Dynamics
- 5.3.1 Liposomal and Lipid-based Nanoparticle Drug Industry Trends
- 5.3.2 Liposomal and Lipid-based Nanoparticle Drug Market Drivers
- 5.3.3 Liposomal and Lipid-based Nanoparticle Drug Market Challenges
- 5.3.4 Liposomal and Lipid-based Nanoparticle Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Liposomal and Lipid-based Nanoparticle Drug Players by Revenue
- 6.1.1 Global Top Liposomal and Lipid-based Nanoparticle Drug Players by Revenue (2021-2026)
- 6.1.2 Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Liposomal and Lipid-based Nanoparticle Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Liposomal and Lipid-based Nanoparticle Drug Head Office and Area Served
- 6.4 Global Liposomal and Lipid-based Nanoparticle Drug Players, Product Type & Application
- 6.5 Global Liposomal and Lipid-based Nanoparticle Drug Manufacturers Established Date
- 6.6 Global Liposomal and Lipid-based Nanoparticle Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Liposomal and Lipid-based Nanoparticle Drug Market Size (2021-2032)
- 7.2 North America Liposomal and Lipid-based Nanoparticle Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2021-2026)
- 7.4 North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size (2021-2032)
- 8.2 Europe Liposomal and Lipid-based Nanoparticle Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2021-2026)
- 8.4 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Liposomal and Lipid-based Nanoparticle Drug Market Size (2021-2032)
- 10.2 South America Liposomal and Lipid-based Nanoparticle Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2021-2026)
- 10.4 South America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Acrotech Biopharma
- 12.1.1 Acrotech Biopharma Company Information
- 12.1.2 Acrotech Biopharma Business Overview
- 12.1.3 Acrotech Biopharma Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
- 12.1.4 Acrotech Biopharma Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
- 12.1.5 Acrotech Biopharma Recent Developments
- 12.2 Alnylam
- 12.2.1 Alnylam Company Information
- 12.2.2 Alnylam Business Overview
- 12.2.3 Alnylam Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
- 12.2.4 Alnylam Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
- 12.2.5 Alnylam Recent Developments
- 12.3 Bausch Health
- 12.3.1 Bausch Health Company Information
- 12.3.2 Bausch Health Business Overview
- 12.3.3 Bausch Health Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
- 12.3.4 Bausch Health Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
- 12.3.5 Bausch Health Recent Developments
- 12.4 Chiesi Farmaceutici
- 12.4.1 Chiesi Farmaceutici Company Information
- 12.4.2 Chiesi Farmaceutici Business Overview
- 12.4.3 Chiesi Farmaceutici Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
- 12.4.4 Chiesi Farmaceutici Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
- 12.4.5 Chiesi Farmaceutici Recent Developments
- 12.5 CSPC
- 12.5.1 CSPC Company Information
- 12.5.2 CSPC Business Overview
- 12.5.3 CSPC Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
- 12.5.4 CSPC Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
- 12.5.5 CSPC Recent Developments
- 12.6 Fudan-Zhangjiang
- 12.6.1 Fudan-Zhangjiang Company Information
- 12.6.2 Fudan-Zhangjiang Business Overview
- 12.6.3 Fudan-Zhangjiang Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
- 12.6.4 Fudan-Zhangjiang Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
- 12.6.5 Fudan-Zhangjiang Recent Developments
- 12.7 Gilead Sciences
- 12.7.1 Gilead Sciences Company Information
- 12.7.2 Gilead Sciences Business Overview
- 12.7.3 Gilead Sciences Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
- 12.7.4 Gilead Sciences Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
- 12.7.5 Gilead Sciences Recent Developments
- 12.8 Ipsen
- 12.8.1 Ipsen Company Information
- 12.8.2 Ipsen Business Overview
- 12.8.3 Ipsen Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
- 12.8.4 Ipsen Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
- 12.8.5 Ipsen Recent Developments
- 12.9 Jazz
- 12.9.1 Jazz Company Information
- 12.9.2 Jazz Business Overview
- 12.9.3 Jazz Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
- 12.9.4 Jazz Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
- 12.9.5 Jazz Recent Developments
- 12.10 Kinyond
- 12.10.1 Kinyond Company Information
- 12.10.2 Kinyond Business Overview
- 12.10.3 Kinyond Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
- 12.10.4 Kinyond Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
- 12.10.5 Kinyond Recent Developments
- 12.11 Leadiant Biosciences
- 12.11.1 Leadiant Biosciences Company Information
- 12.11.2 Leadiant Biosciences Business Overview
- 12.11.3 Leadiant Biosciences Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
- 12.11.4 Leadiant Biosciences Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
- 12.11.5 Leadiant Biosciences Recent Developments
- 12.12 Luye Pharma
- 12.12.1 Luye Pharma Company Information
- 12.12.2 Luye Pharma Business Overview
- 12.12.3 Luye Pharma Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
- 12.12.4 Luye Pharma Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
- 12.12.5 Luye Pharma Recent Developments
- 12.13 Pacira
- 12.13.1 Pacira Company Information
- 12.13.2 Pacira Business Overview
- 12.13.3 Pacira Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
- 12.13.4 Pacira Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
- 12.13.5 Pacira Recent Developments
- 12.14 Sayre Therapeutics
- 12.14.1 Sayre Therapeutics Company Information
- 12.14.2 Sayre Therapeutics Business Overview
- 12.14.3 Sayre Therapeutics Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
- 12.14.4 Sayre Therapeutics Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
- 12.14.5 Sayre Therapeutics Recent Developments
- 12.15 TTY Biopharma
- 12.15.1 TTY Biopharma Company Information
- 12.15.2 TTY Biopharma Business Overview
- 12.15.3 TTY Biopharma Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
- 12.15.4 TTY Biopharma Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
- 12.15.5 TTY Biopharma Recent Developments
- 12.16 Zydus Cadila
- 12.16.1 Zydus Cadila Company Information
- 12.16.2 Zydus Cadila Business Overview
- 12.16.3 Zydus Cadila Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
- 12.16.4 Zydus Cadila Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
- 12.16.5 Zydus Cadila Recent Developments
- 12.17 Johnson & Johnson
- 12.17.1 Johnson & Johnson Company Information
- 12.17.2 Johnson & Johnson Business Overview
- 12.17.3 Johnson & Johnson Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
- 12.17.4 Johnson & Johnson Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
- 12.17.5 Johnson & Johnson Recent Developments
- 12.18 Sun Pharmaceutical
- 12.18.1 Sun Pharmaceutical Company Information
- 12.18.2 Sun Pharmaceutical Business Overview
- 12.18.3 Sun Pharmaceutical Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
- 12.18.4 Sun Pharmaceutical Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
- 12.18.5 Sun Pharmaceutical Recent Developments
- 12.19 Teva
- 12.19.1 Teva Company Information
- 12.19.2 Teva Business Overview
- 12.19.3 Teva Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
- 12.19.4 Teva Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
- 12.19.5 Teva Recent Developments
- 12.20 Takeda
- 12.20.1 Takeda Company Information
- 12.20.2 Takeda Business Overview
- 12.20.3 Takeda Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2021-2026)
- 12.20.4 Takeda Liposomal and Lipid-based Nanoparticle Drug Product Portfolio
- 12.20.5 Takeda Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$2,950USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst